Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349228 | 0.91 | — | — | |
| SCHEMBL30489137 | 0.91 | — | — | |
| SCHEMBL100446 | 0.91 | — | — | |
| SCHEMBL30221685 | 0.88 | TSHR (0.48) | TSHRTRPV4KAT6AESR2CYP11B1 | |
| Bromide SCHEMBL31124413 | 0.88 | TSHR (0.48) | TSHRTRPV4KAT6AESR2CYP11B1 | |
| Benzene SCHEMBL28237898 | 0.88 | TSHR (0.48) | TSHRTRPV4KAT6AESR2CYP11B1 | |
| Hydrochloric Acid SCHEMBL5130070 | 0.88 | TSHR (0.48) | TSHRTRPV4KAT6AESR2CYP11B1 | |
| SCHEMBL28236276 | 0.88 | TSHR (0.48) | TSHRTRPV4KAT6AESR2CYP11B1 | |
| SCHEMBL28303806 | 0.88 | TSHR (0.48) | TSHRTRPV4KAT6AESR2CYP11B1 | |
| Boric Acid SCHEMBL29090056 | 0.86 | TSHR (0.43) | TSHRTRPV4KAT6AESR2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| CN-111675626-A | Ionone alkaloid derivative and medical application thereof | 天津医科大学 | 2020-09-18 | — | — | CN | disclosed |
| EP-3558972-A1 | TETRAZOLE CONTAINING COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3394044-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2018114783-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-2501232-A1 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | Merck Sharp & Dohme Corp. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120225885-A1 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2012-09-06 | — | — | US | disclosed |
| EP-2396301-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011060235-A1 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010091876-A2 | SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | TSHR 2535/4885TRPV4 86/4885KAT6A 2732/4885 |
| US-20120225885-A1 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GID4, SI | TSHR 2689/4885TRPV4 159/4885KAT6A 2644/4885 |
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | TSHR 2808/4885TRPV4 4355/4885KAT6A 436/4885 |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TSHR 2808/4885TRPV4 4355/4885KAT6A 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.